Find relevant news articles from other European projects, below:
Browse our carefully curated library of the latest news and developments in all areas of immunotherapy here:
Browse this week's featured selection of scientific publications
A new selection of scientific publications relating to the latest developments in immunotherapy are added to our website weekly. Here are this week's must-read highlights.
Interim data of D-ALBA study: blinatumomab and TKI therapy as consolidation and ...
Prof Geyer speaks to ecancer about an ongoing phase II study which has been presented at this year’s ASH virtual conference regarding blinatumomab and concurrent oral tyrosine kinase inhibitor therapy as consolidation and maintenance therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia following chemotherapy-sparing induction.
Chemo-free therapy for adult Ph+ ALL
A targeted and immunotherapeutic strategy including dasatinib and the bispecific mAb blinatumomab is able to successfully treat adult patients with Philadelphia-positive acute lymphoblastic leukemia (ALL), inducing 98% of hematological CR and 60% of molecular responses. These results, published on NEJM, were obtained without adding of chemotherapy, an innovative approach associated with high survival rates and few toxic effects.